Pediatric Ulcerative Colitis: A Practical Guide to Management

被引:17
作者
Regan, Brian P. [1 ]
Bousvaros, Athos [1 ]
机构
[1] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Gastroenterol,Inflammatory Bowel Dis Ctr,GI, Boston, MA 02115 USA
关键词
INFLAMMATORY-BOWEL-DISEASE; OPTIMIZE AZATHIOPRINE THERAPY; COMBINATION THERAPY; DOUBLE-BLIND; MAINTENANCE THERAPY; ORAL TACROLIMUS; CROHNS-DISEASE; OLMSTED COUNTY; CLINICAL-USE; METHOTREXATE;
D O I
10.1007/s40272-014-0070-8
中图分类号
R72 [儿科学];
学科分类号
100202 [儿科学];
摘要
Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract of unknown etiology that frequently presents in the pediatric population. The evaluation of pediatric UC involves excluding infection, and a colonoscopy that documents the clinical and histologic features of chronic colitis. Initial management of mild UC is typically with mesalamine therapy for induction and maintenance. Moderate UC is often initially treated with oral prednisone. Depending on disease severity and response to prednisone, maintenance options include mesalamine, mercaptopurine, azathioprine, infliximab, or adalimumab. Severe UC is typically treated with intravenous corticosteroids. Corticosteroid nonresponders should either undergo a colectomy or be treated with second-line medical rescue therapy (infliximab or calcineurin inhibitors). The severe UC patients who respond to medical rescue therapy can be maintained on infliximab or thiopurine, but 1-year remission rates for such patients are under 50 %. These medications are discussed in detail along with the initial work-up and a treatment algorithm.
引用
收藏
页码:189 / 198
页数:10
相关论文
共 76 条
[1]
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease [J].
Afif, Waqqas ;
Loftus, Edward V., Jr. ;
Faubion, William A. ;
Kane, Sunanda V. ;
Bruining, David H. ;
Hanson, Karen A. ;
Sandborn, William J. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05) :1133-1139
[2]
Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre [J].
Aloi, M. ;
Di Nardo, G. ;
Conte, F. ;
Mazzeo, L. ;
Cavallari, N. ;
Nuti, F. ;
Cucchiara, S. ;
Stronati, L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (08) :1017-1022
[3]
[Anonymous], 2007, J PEDIATR GASTR NUTR, V44, P653
[4]
Toxic megacolon [J].
Autenrieth, Daniel M. ;
Baumgart, Daniel C. .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (03) :584-591
[5]
TREATMENT OF DISTAL ULCERATIVE-COLITIS WITH BECLOMETHASONE ENEMAS - HIGH THERAPEUTIC EFFICACY WITHOUT ENDOCRINE SIDE-EFFECTS - A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL [J].
BANSKY, G ;
BUHLER, H ;
STAMM, B ;
HACKI, WH ;
BUCHMANN, P ;
MULLER, J .
DISEASES OF THE COLON & RECTUM, 1987, 30 (04) :288-292
[6]
BARON J H, 1962, Br Med J, V2, P441
[7]
Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis [J].
Beattie, RM ;
Nicholls, SW ;
Domizio, P ;
Williams, CB ;
WalkerSmith, JA .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1996, 22 (04) :373-379
[8]
TUMOR-NECROSIS-FACTOR ALPHA-PRODUCING CELLS IN THE INTESTINAL-MUCOSA OF CHILDREN WITH INFLAMMATORY BOWEL-DISEASE [J].
BREESE, EJ ;
MICHIE, CA ;
NICHOLLS, SW ;
MURCH, SH ;
WILLIAMS, CB ;
DOMIZIO, P ;
WALKERSMITH, JA ;
MACDONALD, TT .
GASTROENTEROLOGY, 1994, 106 (06) :1455-1466
[9]
Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation [J].
Brunner, M ;
Ziegler, S ;
Di Stefano, AFD ;
Dehghanyar, P ;
Kletter, K ;
Tschurlovits, M ;
Villa, R ;
Bozzella, R ;
Celasco, G ;
Moro, L ;
Rusca, A ;
Dudczak, R ;
Müller, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (01) :31-38
[10]
Side effects of corticosteroid therapy [J].
Buchman, AL .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2001, 33 (04) :289-294